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Abstract
Background: The secreted liver protein fetuin-A (AHSG) is up-regulated in hepatic steatosis and the metabolic syndrome.
These states are strongly associated with low-grade inflammation and hypoadiponectinemia. We, therefore, hypothesized
that fetuin-A may play a role in the regulation of cytokine expression, the modulation of adipose tissue expression and
plasma concentration of the insulin-sensitizing and atheroprotective adipokine adiponectin.
Methodology and Principal Findings: Human monocytic THP1 cells and human in vitro differenttiated adipocytes as well as
C57BL/6 mice were treated with fetuin-A. mRNA expression of the genes encoding inflammatory cytokines and the
adipokine adiponectin (ADIPOQ) was assessed by real-time RT-PCR. In 122 subjects, plasma levels of fetuin-A, adiponectin
and, in a subgroup, the multimeric forms of adiponectin were determined. Fetuin-A treatment induced TNF and IL1B mRNA
expression in THP1 cells (p,0.05). Treatment of mice with fetuin-A, analogously, resulted in a marked increase in adipose
tissue Tnf mRNA as well as Il6 expression (27- and 174-fold, respectively). These effects were accompanied by a decrease in
adipose tissue Adipoq mRNA expression and lower circulating adiponectin levels (p,0.05, both). Furthermore, fetuin-A
repressed ADIPOQ mRNA expression of human in vitro differentiated adipocytes (p,0.02) and induced inflammatory
cytokine expression. In humans in plasma, fetuin-A correlated positively with high-sensitivity C-reactive protein, a marker of
subclinical inflammation (r=0.26, p=0.01), and negatively with total- (r=20.28, p=0.02) and, particularly, high molecular
weight adiponectin (r=20.36, p=0.01).
Conclusions and Significance: We provide novel evidence that the secreted liver protein fetuin-A induces low-grade
inflammation and represses adiponectin production in animals and in humans. These data suggest an important role of
fatty liver in the pathophysiology of insulin resistance and atherosclerosis.
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Introduction
Fetuin-A (former name for the human protein: a2-Heremans-
Schmid glycoprotein, AHSG) is an abundant serum protein [1]
that is exclusively produced by the liver, tongue, and placenta [2].
In several studies, fetuin-A was shown to act as a natural inhibitor
of the insulin receptor tyrosine kinase in liver and skeletal muscle
[3–7]. In addition, mice deficient for the gene encoding fetuin-A
displayed improved insulin sensitivity and were resistant to weight
gain upon a high-fat diet [8]. Besides these well-documented
effects of fetuin-A on the insulin receptor of muscle and liver,
another mechanism of this protein may include effects on adipose
tissue to induce whole-body insulin resistance. Recently, polymor-
phisms in the gene encoding human fetuin-A were found to be not
only associated with type 2 diabetes [9], but also to affect insulin
action in adipocytes [10]. Furthermore, fetuin-A was shown to
exert direct pro-adipogenic properties [11], however, the under-
lying mechanisms are unknown.
The genes encoding human fetuin-A (AHSG) and human
adiponectin (ADIPOQ), which is almost exclusively secreted from
adipose tissue and represents an important determinant of whole-
body insulin sensitivity [12–16] and cardiovascular disease [17–20],
are located next to each other on chromosome 3q27. This
chromosomal region was previously mapped as a type 2 diabetes
and metabolic syndrome susceptibility locus [21,22], and also shows
closelinkagetovariationinplasmaadiponectinlevels[23].However,
notallofthevariabilityinplasmaadiponectinlevelscanbeexplained
bygeneticvariationoftheADIPOQgene[23].Therefore,othergenes
under this linkage peak may encode proteins regulating adiponectin
production with AHSG representing a major candidate.
Recently, we and others have shown that human plasma fetuin-
A levels are correlated with fatty liver, impaired glucose tolerance,
PLoS ONE | www.plosone.org 1 March 2008 | Volume 3 | Issue 3 | e1765and insulin resistance [24,25]. Moreover, a recent study provided
evidence that human plasma fetuin-A levels are strongly associated
with the metabolic syndrome and an atherogenic lipid profile [26].
Since these states are characterized by subclinical inflammation
and hypoadiponectinemia [27], and based on the chromosomal
localization of AHSG, we investigated whether fetuin-A regulates
cytokine expression, modulates adipose tissue expression and the
plasma concentration of the insulin-sensitizing and atheroprotec-
tive adipokine adiponectin.
Material and Methods
Cell culture
Human THP1 monocytes were obtained from American Type
Culture Collection (Manassas, VA, USA) and cultured in IMDM
supplemented with 10% (v/v) FCS, 100 IU/ml penicillin, 0.1 mg/
ml streptomycin, and 2 mmol/l glutamine. Cells were left
untreated or stimulated for 8 and 24 h with 600 mg/ml human
fetuin-A (purity $95%, Sigma-Aldrich, Steinheim, Germany), a
high physiological dose, or human serum albumin for control
(ZLB Behring, Marburg, Germany), respectively.
Human preadipocytes were isolated from abdominal subcuta-
neous fat biopsies as previously described [28]. The donors
underwent abdominal surgery for clinical purposes and gave
informed written consent to the study. Isolated preadipocytes were
expanded in a-MEM/Ham’s nutrient mixture F12 (1:1) contain-
ing 20% (v/v) FCS, 1% (v/v) chicken embryo extract (Sera
Laboratories International, Horsted Keynes, UK), 100 IU/ml
penicillin, 0.1 mg/ml streptomycin, 0.5 mg/ml fungizone, and
2 mmol/l glutamine. First-pass cells were used for the experi-
ments. At confluence, adipose conversion was induced by shifting
the cells into DMEM/Ham’s nutrient mixture F12 (1:1), 5% (v/v)
FCS, 17 mmol/l pantothenate, 1 mmol/l biotin, 2 mg/ml apo-
transferrin, 1 mmol/l insulin, 100 IU/ml penicillin, 0.1 mg/ml
streptomycin, 0.5 mg/ml fungizone, and 2 mmol/l glutamine
(differentiation medium) supplemented with 0.5 mmol/l 3-isobu-
tyl-1-methyl-xanthine, 1 mmol/l cortisol, 10 mmol/l troglitazone,
and 50 mmol/l indomethacin for 7 days. Finally, the cells
were allowed to terminally differentiate for another 7 days in
differentiation medium without supplements. Medium was
changed three times a week. In vitro differentiated adipocytes
were washed once with PBS and pretreated overnight with insulin-
and FCS-free differentiation medium. Thereafter, cells were
incubated for 24 h with or without 300 mg/ml human or bovine
fetuin-A, respectively, in insulin- and FCS-free differentiation
medium prior to RNA isolation. The procedures were approved
by the Ethical Committee of the Tu ¨bingen University Medical
Department.
Animal studies
Male C57BL/6 mice were obtained from Charles River
Laboratories (Sulzfeld, Germany). For in vivo stimulation, 12-
week-old C57BL/6 mice kept on a regular diet obtained an
intraperitoneal bolus of bovine fetuin-A (fetuin-I, Pedersen’s
preparation, purity ,75%, 0.75 mg/g body weight, ICN,
Eschwege, Germany), human fetuin-A (0.5 mg/g body weight),
or human serum albumin (0.5 mg/g body weight), respectively.
Controls received a comparable amount of diluent (n $ 3 each).
Serum and perigonadal adipose tissue were removed after 8 h.
Tissue samples were stored at 4uC in RNAlater (Ambion,
Huntingdon, United Kingdom). All procedures were conducted
according to the guidelines of laboratory animal care and were
approved by the local governmental commission for animal
research. Insulin resistance was estimated by the homeostasis
model assessment of insulin resistance (HOMA-IR) and calculated
as insulin (mU/ml) ? glucose (mM)/22.5 [29].
Real-time RT-PCR
For quantification of mRNA expression in mouse adipose tissue,
RNA was isolated with peqGOLD TriFast according to the
manufacturer’s instructions (Peqlab, Erlangen, Germany). For
quantification of THP1 monocyte and human adipocyte mRNA,
cells were washed, harvested, and RNA was isolated with RNeasy
silica-gel columns according to the manufacturer’s instructions
(Qiagen, Hilden, Germany). The total RNA was treated with
RNase-free DNase I and transcribed into cDNA using AMV
reverse transcriptase and the first strand cDNA kit from Roche
Diagnostics (Mannheim, Germany). Quantitative PCR was
performed with SYBR Green I dye on a high speed thermal
cycler with integrated microvolume fluorometer according to the
instructions of the manufacturer (Roche Diagnostics, Mannheim,
Germany). Primers were obtained from Invitrogen (Karlsruhe,
Germany) and PCR conditions are given in Table 1. Measure-
ments were performed in triplicate. Cellular mRNA contents are
given, after correction for 28S-rRNA, in relative arbitrary units
(RAU or % of control).
Human subjects
A total of 122 individuals were studied. These subjects were at
increased risk for type 2 diabetes and participated in an ongoing
study [24]. Individuals were recruited from the southern part of
Germany and were not related to each other. The participants did
not take any medication known to affect glucose tolerance or
insulin sensitivity. Informed written consent was obtained from all
participants, and the Ethical Committee of the Tu ¨bingen
University Medical Department had approved the protocol.
Hyperinsulinemic euglycemic clamp
Insulin sensitivity was determined in 49 human subjects as
previously described [24]. In brief, subjects received a primed
insulin infusion at a rate of 40 mU?m
22?min
21 for 2 h. Plasma
was drawn every 5 min for determination of plasma glucose, and
glucose infusion was adjusted appropriately to maintain the fasting
glucose level. An insulin sensitivity index for systemic glucose
uptake (ISI; in mmol kg
21 min
21 pM
21) was calculated as the
mean infusion rate of glucose (in mol kg
21 min
21) necessary to
maintain euglycemia during the last 40 min of the hyperinsulin-
emic euglycemic clamp divided by the steady state plasma insulin
concentration. The latter was the mean insulin concentration at
min 100, 110, and 120 of the clamp (522619 pM).
Other analytical procedures
Plasma glucose was determined using a bedside glucose analyzer
(glucose oxidase method; Yellow Springs Instruments, Yellow
Springs, CO, USA). Plasma insulin was determined by an enzyme
immunoassay (Abbott Laboratories, Tokyo, Japan). Serum
adiponectin levels in mice and fasting plasma fetuin-A levels in
human subjects were measured using commercial enzyme-linked
immunosorbent assays (ELISA, BioVendor Laboratory Medicine,
Brno, Czech Republic). ELISAs were also used to measure serum
concentrations of TNF-a, IL-6, and high sensitivity C-reactive
protein (hsCRP, R&D Systems Inc., MN, USA). Fasting plasma
adiponectin levels in humans were determined by radioimmuno-
assay (LINCO Research, St. Charles, MO, USA). Multimeric
forms of adiponectin were quantified using an enzyme immuno-
assay (ALPCO Diagnostics, Salem, NH, USA). Percentage of body
fat was assessed by bioelectrical impedance.
Fetuin-A and Adiponectin
PLoS ONE | www.plosone.org 2 March 2008 | Volume 3 | Issue 3 | e1765Statistical analyses
Data are given as means6SEM. For 3-group comparisons, data
were analyzed by ANOVA followed by Dunnett’s test. Statistical
comparison between treatment and control group were performed
with the Student’s t-test. To adjust for the effects of relevant
covariates (age, gender, body fat) in the in vivo data, multivariate
linear regression analysis was performed using log-transformed
data. A p-value ,0.05 was considered statistically significant. The
statistical software package JMP 4.0 (SAS Institute Inc, Cary, NC,
USA) was used.
Results
Effect of fetuin-A on cytokine mRNA expression of
human THP1 monocytes
Human THP1 monocytes were treated with human fetuin-A
and, to evaluate the specificity of fetuin-A’s effect and as control
for general trophic effects, additionally with human albumin
(600 mg/ml, each) for 8 h. Human fetuin-A induced the mRNA
expression of TNF (ANOVA,F(14,12)=9.07, p=0.004,Figure 1A)
and IL1B (ANOVA, F(14,12)=4.27, p=0.075, Figure 1B), but did
not modulate mRNA expression of PBEF1 (encoding visfatin,
Figure 1C) or RETN (encoding resistin, Figure 1D). Human
albumin as a control did not significantly alter the expression of all
these genes (Figure 1A–D). The IL6 mRNA expression in these
cells was below the detection limit.
Effect of fetuin-A on adipose tissue Adipoq mRNA
expression and circulating adiponectin in mice
Within 8 h, intraperitoneal bolus administration of human
fetuin-A (0.5 mg/g body weight) into male C57BL/6 mice
resulted in insulin resistance (fetuin-A-treated: 22.4661.27 vs
control: 10.2161.65, T(4)=9.06, p=0.004) as estimated by the
HOMA-IR. Furthermore, fetuin-A induced adipose tissue mRNA
expression of the inflammatory genes Il6 and Tnf 174- and 27-fold
(ANOVA, F(9,7)=7.12, p=0.02, and F(9,7)=12.38, p=0.005,
respectively, Figure 2A,B). This was accompanied by a 58%
decrease in adipose tissue Adipoq mRNA content as compared to
control (ANOVA, F(9,7)=6.15, p=0.038, Figure 2C), that
showed a strong trend after correction for multiple comparison
(p=0.06). To validate these findings on Adipoq mRNA expression,
we repeated the experiment and additionally measured serum
adiponectin. In the second experiment, treatment of mice with a
commercially available bovine fetuin-A (0.75 mg/g body weight)
provoked a significant 45% decrease in perigonadal adipose tissue
Adipoq mRNA content as compared to baseline (T(4)=4.30,
p=0.006), whereas no effect was seen in diluent-treated control
animals (p=0.48). Concomitantly, serum adiponectin levels
significantly decreased in fetuin-A-treated (T(4)=2.58,
p=0.031), but not in diluent-treated mice (p=0.41). To assess
specificity for adiponectin, we additionally quantified adipose
tissue mRNA expression of other adipokine genes such as Lep
(encoding leptin) and Rbp4 (encoding retinol-binding protein 4).
Fetuin-A did not modulate Lep (Figure 2D) or Rbp4 (data not
shown) mRNA expression. Treatment of mice with human
albumin (0.5 mg/g body weight) did not significantly alter the
expression of all these genes (all p.0.2, Figure 2A–D).
Effect of fetuin-A on ADIPOQ and cytokine mRNA
expression of human in vitro differentiated adipocytes
To test whether suppression of Adipoq mRNA expression by
fetuin-A is a direct effect on adipocytes and is not restricted to
rodents, we treated in vitro differentiated human adipocytes from
four donors with bovine or human fetuin-A (300 mg/ml) for 24 h.
These procedures resulted in 30- and 50-% reductions of ADIPOQ
mRNA expression, respectively (T(3)=23.87, p=0.001 and
T(3)=23.54, p=0.016, respectively, Figure 3). In analogy to
our results in human THP1 monocytes, fetuin-A induced
inflammatory markers in adipocytes as well (TNF: p=0.007;
IL6: p=0.035; CCL2: p=0.03; IL1B: p=0.068, data not shown).
Table 1. Conditions for RT-PCR quantification of specific mRNAs and 28S-rRNA.
RNA Forward primer (59R39) Reverse primer (59R39)
Tannealing
(uC)
No. of
cycles
MgCl2
(mM)
Murine
Adipoq mRNA GGTGAGACAGGAGATGTTGG CCTGATACTGGTCGTAGG TG 64 45 3
Lep mRNA ACATTTCACACACGCAGTCG AGC ATT CAG GGC TAA CAT CC 69 55 5
Il6 mRNA GATGCTACCAAACTGGATATAATC GGTCCTTAGCCACTCCTTCTGTG 65 45 6
Tnf mRNA AAATGGCCTCCCTCTCATCA AGATAGCAAATCGGCTGACG 63 45 3
Rbp4 mRNA GTTTTCTCGTGACCCCAATG GGAGGTGGGGGAAACTAAAC 68 50 3
28S-rRNA CCAGTACTTCACTCCTGTCT TCTAAGAGTGAGCAACGACG 61 45 3
Human
ADIPOQ mRNA GTGATGGCAGAGATGGCAC AGAGGCTGACCTTCACATCC 65 45 4
IL6 mRNA CCAGCTATGAACTCCTTCTC GCTTGTTCCTCACATCTCTC 63 45 3
TNF mRNA GCGTGGAGCTGAGAGATAAC GATGTTCGTCCTCCTCACAG 61 45 4
IL1B mRNA* CATGGACAAGCTGAGGAAGA TTCAACACGCAGGACAGGTA 61 45 4
PBEF1 mRNA TCCAGGAAGCCAAAGATGTC GGCCACTGTGATTGGATACC 61 40 3
RETN mRNA GCCGGATTTGGTTAGCTGAG CTCATTGATGGCTTCTTCCA 66 40 6
CCL2 mRNA GCCTCCAGCATGAAAGTCTC TGGAATCCTGAACCCACTTC 61 40 3
28S-rRNA ACG GCG GGA GTA ACT ATG ACT CTT GGC TGT GGT TTC GCT 63 50 4
*For detection of IL1B mRNA, the fluorescent dye-linked probes 59-AGGTGCTCAGGTCATTCTCCTGG-FL-39 and 59-Red640-AGGTCTGTGGGCAGGGAACC-PH-39 were used
instead of SYBR Green.
doi:10.1371/journal.pone.0001765.t001
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fetuin-A exist, we determined the fetuin-A mRNA expression in
human THP1 monocytes and human adipose tissue and for
comparison in human liver. While fetuin-A was expressed in liver
tissue from human donors, it was not expressed in THP1
monocytes or adipose tissue (Figure S1). Furthermore, fetuin-A
expression was not detected in adipose tissue from obese and
insulin resistant Pima Indians (personal communication Dr. Paska
Permana) suggesting that these conditions do not induce fetuin-A
expression in adipose tissue in humans. Thus, these data strongly
support that the endocrine action of fetuin-A mediates the
aforementioned effects.
Relationship of plasma fetuin-A with circulating markers
of inflammation and plasma adiponectin
To investigate whether plasma fetuin-A is associated with
circulating markers of inflammation and circulating adiponectin in
humans in vivo, we analyzed cross-sectional data from 122 subjects
including 80 subjects with normal glucose tolerance, 40 subjects
with impaired glucose tolerance, and two patients with newly
diagnosed and untreated type 2 diabetes. The subjects covered a
wide range of age, body fat content, waist circumference, and
circulating fetuin-A (Table 2). Plasma fetuin-A was not associated
with circulating IL-6 and TNF-a (both p $ 0.82). This finding was
not unexpected since both cytokines act in a paracrine, rather than
in a systemic fashion [30]. However, a positive correlation between
circulating fetuin-A and hsCRP, a systemic marker of subclinical
inflammation, was detected (r=0.26, p=0.01, n=94 with hsCRP
above the detection limit of the ELISA). Furthermore, circulating
fetuin-A and adiponectin were negatively correlated with each
other (r=20.28, p=0.02).
Next, we assessed the role of plasma fetuin-A as a determinant
of circulating adiponectin and its independence of other known
determinants of circulating adiponectin by multivariate linear
regression analysis (Table 3). Circulating adiponectin was chosen
as the dependent variable, and gender, age, body fat, and waist
circumference were used as covariates and added step by step
(Table 3, models 1–4). This procedure gradually increased the r
2
of the model to 0.39 (Table 3, model 4). Inclusion of plasma fetuin-
A as an additional covariate further increased the r
2 to 0.42, and
plasma fetuin-A concentration turned out to be an independent
determinant of circulating adiponectin (Table 3, model 5).
Figure 1. mRNA expression in human THP1 monocytes following fetuin-A treatment. Expression of TNF (A), IL1B (B), PBEF1 (C), and RETN
(D) mRNA in human THP1 monocytes before (control) and after treatment with human albumin or human fetuin-A for 8 h. Cellular mRNA contents
were corrected for 28S-rRNA (RAU=relative arbitrary units). Data are given as means6SEM (n=5). Data were analyzed by ANOVA, followed by
Dunnett’s test.
doi:10.1371/journal.pone.0001765.g001
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adiponectin
Plasma adiponectin circulates in several multimeric forms, i.e.
trimeric low molecular weight (LMW), hexameric middle
molecular weight (MMW) as well as more complex high molecular
weight (HMW) structures [31]. We assessed whether fetuin-A
affects the formation of a certain form in a subgroup of 49 subjects
who underwent the clamp and had plasma samples stored at
280uC (21 men, 28 women; 23–64 years; 16.0–50.0% body fat;
68–119 cm waist circumference). In this subgroup, total plasma
adiponectin was positively correlated with hyperinsulinemic
euglycemic clamp-derived insulin sensitivity adjusted for gender,
age, and body fat (r=0.40, p=0.005). Furthermore, plasma
fetuin-A tended to negatively correlate with the adjusted insulin
sensitivity (r=20.25, p=0.08) reflecting our recent data [24].
Plasma fetuin-A correlated negatively with total adiponectin
(Figure 4A) and, in particular, with HMW (Figure 4B) and
MMW (Figure 4C) adiponectin, but not with LMW adiponectin
(Figure 4D).
Discussion
Fetuin-A is a major plasma glycoprotein which was dis-
covered in 1944 [32]. For a long time, its biological function
remained obscure. Using targeted gene disruption, fetuin-A was
recently reported to inhibit ectopic calcification [33,34]. In
keeping with this, fetuin-A deficiency in humans was found to
be associated with vascular calcification and mortality in patients
on hemodialysis [35]. However, fetuin-A might exert more
functions: several studies demonstrated that fetuin-A can act as
a natural inhibitor of the insulin receptor tyrosine kinase in liver
and skeletal muscle [3–7], and fetuin-A knockout mice display
improved insulin sensitivity and are resistant to weight gain upon a
high-fat diet [8].
Besides the effects of fetuin-A on muscle and liver insulin
signalling, there is increasing evidence that fetuin-A is important
for insulin action in adipose tissue [10]. Moreover, the variability
of plasma adiponectin levels is largely explained by a locus on
human chromosome 3q27 harbouring both ADIPOQ and, in direct
vicinity, AHSG. It is of note that not all variability in plasma
Figure 2. Cytokine and adipokine mRNA expression in adipose tissue of mice. Adipose tissue expression of Il6 (A), Tnf (B), Adipoq (C), and
Lep (D) mRNA in mice after bolus treatment with human fetuin-A (0.5 mg/g body weight), human albumin (0.5 mg/g body weight), or diluent
(control) for 8 h. Cellular mRNA contents were corrected for 28S-rRNA (RAU=relative arbitrary units). Data are given as means6SEM. Data were
analyzed by ANOVA, followed by Dunnett’s test.
doi:10.1371/journal.pone.0001765.g002
Fetuin-A and Adiponectin
PLoS ONE | www.plosone.org 5 March 2008 | Volume 3 | Issue 3 | e1765adiponectin is explained by genetic variation of the ADIPOQ gene
[23]. This led us to investigate whether fetuin-A regulates
adiponectin production and, thus, may explain the recently
reported association between fetuin-A and the metabolic syn-
drome [24,25]. In addition, the metabolic syndrome and
hypoadiponectinemia are strongly associated with low-grade
inflammation [27]. Furthermore, high circulating fetuin-A was
found to be associated with carotid arterial stiffness [36], a
functional property of atherosclerosis that is accompanied by
subclinical inflammation. Therefore, we further tested whether
Figure 3. Adiponectin mRNA expression in cultured human
adipocytes. ADIPOQ mRNA expression of human in vitro differentiated
adipocytes after treatment with bovine (A) and human (B) fetuin-A for
24 h. Cellular mRNA contents were corrected for 28S-rRNA. Data from
adipocyte cultures of four donors are presented. Data were analyzed by
Student’s t-test.
doi:10.1371/journal.pone.0001765.g003
Table 2. Demographics and metabolic characteristics of the
subjects
Variables Mean6SE Range
Gender (Males/Females) 50/72
Age (years) 44611 9 – 6 5
Height (cm) 171611 4 9 – 1 9 3
Weight (kg) 85625 2 – 1 6 6
Waist circumference (cm) 97615 6 – 1 5 0
Body fat (%) 32611 0 – 5 4
Insulin sensitivity
(mMk g
21 min
21 pM
21)
0.06460.004 0.010–0.200
hsCRP (mg/ml) 0.2060.03 0.01–1.54
TNF-a (pg/ml) 4.1960.81 0.06–55.44
Il-6 (pg/ml) 0.9360.23 0.04–25.93
Total adiponectin (mg/ml) 9.0060.41 2.92–24.58
Total adiponectin (mg/ml)* 6.4360.44 2.45–17.47
LMW adiponectin (mg/ml)* 2.3660.24 0.46–8.83
MMW adiponectin (mg/ml)* 1.4960.15 0.30–4.86
HMW adiponectin (mg/ml)* 2.5860.24 0.49–7.81
Fetuin-A (mg/ml) 264610 111–604
Values are mean (SE);
*available in 49 subjects
doi:10.1371/journal.pone.0001765.t002
Table 3. Determinants of circulating adiponectin in humans
in multivariate linear regression models
Covariates Estimate6SE p
Model 1 (r
2=0.31)
Female sex 0.26860.036 ,0.0001
Model 2 (r
2=0.34)
Female sex 0.27560.036 ,0.0001
Age 0.26160.036 0.03
Model 3 (r
2=0.38)
Female sex 0.33560.041 ,0.0001
Age 0.23960.116 0.04
Body fat 21.22460.441 0.006
Model 4 (r
2=0.39)
Female sex 0.25360.062 ,0.0001
Age 0.26860.117 0.02
Body fat 20.37660.650 0.56
Waist circumference 20.63460.359 0.08
Model 5 (r
2=0.42)
Female sex 0.24760.061 ,0.0001
Age 0.18760.119 0.12
Body fat 20.29360.638 0.65
Waist circumference 20.60160.352 0.09
Plasma Fetuin-A 20.23460.097 0.02
doi:10.1371/journal.pone.0001765.t003
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critical step in the generation of low-grade inflammation.
With the present report, we provide novel data that highly
purified fetuin-A exerts strong pro-inflammatory effects as it
provoked cytokine expression in monocytes in vitro. The latter are
known to infiltrate hypertrophic adipose tissue and to essentially
contribute to adipose tissue inflammation [37,38]. In addition, we
found that, in animals in vivo, fetuin-A treatment increased
adipose tissue RNA expression of Il6 and Tnf 174- and 27-fold,
respectively.
Besides the effects of fetuin-A on the expression of these
inflammatory cytokines, administration of fetuin-A into mice
repressed Adipoq mRNA expression in adipose tissue and decreased
circulating adiponectin. Lep and Rbp4 mRNA expression were not
affected by fetuin-A, and albumin did not impair Adipoq mRNA
expression. These findings provide evidence that the effect of
fetuin-A on Adipoq expression is not due to a general trophic effect
[39]. Furthermore, fetuin-A directly affected adipocyte gene
expression and these findings were not restricted to rodents: it
repressed ADIPOQ expression of in vitro differentiated human
adipocytes.
Based on these findings in vitro and in animals, we further
investigated whether circulating fetuin-A was related to low-grade
inflammation and circulating adiponectin in humans. Indeed,
plasma fetuin-A levels correlated positively with hsCRP levels, as
reported previously by Ix et al. [26].
These findings are somewhat unexpected because CRP is up-
regulated in inflammatory states while acute inflammation down-
regulates fetuin-A expression in the liver [40]. Whether, the latter
effect is transient and/or reflects compensational mechanisms,
needs to be determined. Furthermore, plasma fetuin-A levels
correlated negatively with plasma adiponectin levels. In addition,
besides other determinants of adiponectin levels, plasma fetuin-A
levels were identified as a contributor to the variability in
circulating adiponectin. Of note, the observed relationships of
fetuin-A with adiponectin in humans were not very strong,
Figure 4. Relationships between circulating fetuin-A and circulating adiponectin in humans. Relationship between plasma levels of
fetuin-A with total adiponectin and adiponectin’s multimeric forms (A–D) in 49 healthy human subjects after adjustment of log-transformed data for
age, sex, and percentage of body fat by multivariate linear regression analysis. The regression coefficients as well as the p-value are indicated (HMW–
high molecular weight; LMW–low molecular weight; MMW–middle molecular weight).
doi:10.1371/journal.pone.0001765.g004
Fetuin-A and Adiponectin
PLoS ONE | www.plosone.org 7 March 2008 | Volume 3 | Issue 3 | e1765nevertheless, they remained statistically significant after adjust-
ment for established determinants of plasma adiponectin levels.
This finding supports the assumption of Ix et al. [26] that the
strong relationship between plasma fetuin-A levels and the
metabolic syndrome may be a result of fetuin-A-induced
suppression of adiponectin production.
In addition, fetuin-A was specifically associated with HMW and
MMW forms of adiponectin, but not with the LMW form. HMW
adiponectin is reported to be the most active adiponectin form [41]
and represents, among all multimeric forms of adiponectin, the
major determinant of insulin resistance, an atherogenic lipoprotein
profile, and the metabolic syndrome [41–43]. How fetuin-A
determines the assembly of trimeric adiponectin into hexameric
MMWandhigher-orderHMWstructures,aprocessthatissupposed
tooccurduringtheentryofadiponectin into thebloodstream[31],is
currently unknown and needs further investigation.
So far, no information is available on fetuin-A-specific cell
surface receptors and intracellular signaling pathways making it
difficult to assess the molecular mechanisms underlying fetuin-A-
induced repression of ADIPOQ expression in adipocytes as well as
fetuin-A-mediated induction of cytokine expression in monocytes
and adipocytes. Since the ADIPOQ gene is under the control of the
transcription factor peroxisome proliferator-activated receptor
(PPAR) c, we also assessed whether PPARc expression was altered
by fetuin-A treatment. Whereas fetuin-A reduced adipose tissue
PPARc expression in mice in vivo, PPARc expression of
adipocytes was not affected (data not shown). The down-regulation
of adiponectin and possibly PPARc expression, appears contra-
dicting to the reported pro-adipogenic effect of fetuin-A [11].
However, this observation may be due to differential effects of
fetuin-A on mature adipocytes and pre-adipocytes, respectively.
Since we observed a strong effect of fetuin-A on cytokine
expression, and IL-6 and TNF-a are well-described negative
regulators of adiponectin expression and production [44–49], we
suppose that fetuin-A-induced impairment of adiponectin synthe-
sis may be at least partially mediated by effects of fetuin-A on IL-6
and TNF-a production. Whether this is an exclusive mechanism,
or whether fetuin-A regulates adiponectin expression and secretion
independently of cytokine production, needs to be determined in
future studies.
Together, the results presented in this work advance our
understanding of the role of fetuin-A in the pathophysiology of
insulin resistance, atherosclerosis, and the metabolic syndrome.
Hepatic steatosis that is strongly related to insulin resistance and
type 2 diabetes [50], associates with enhanced hepatic fetuin-A
production in rats [51] and humans [24]. Elevated circulating
levels of fetuin-A negatively affect whole-body insulin sensitivity (i)
by impairment of insulin signaling in muscle and liver [3–7] and
(ii) by triggering inflammation in adipose tissue and suppression of
adiponectin production. Generation of an atherogenic lipoprotein
profile [52], induction of inflammatory cytokines as well as
suppression of the atheroprotective hormone adiponectin [53],
therefore, represent plausible molecular pathways linking fatty
liver and atherosclerosis [54]. In addition, based on the findings
from fetuin-A deficient mice that remain lean and insulin sensitive
fed a high-fat diet [8], fetuin-A may have long-term effects on
energy expenditure and lipid oxidation, independent of the
aforementioned mechanisms.
In conclusion, we found that fetuin-A induces low-grade
inflammation and represses adiponectin production in animals
and in humans. These data provide novel evidence on the role of
fatty liver in the pathophysiology of insulin resistance and
atherosclerosis.
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Acknowledgments
The authors thank all study participants for their cooperation. We
gratefully acknowledge the excellent technical assistance of Anna Bury and
Heike Luz who were involved in the clinical tests and Melanie Weisser and
Alke Guirguis who were involved in the analytical procedures.
Author Contributions
Conceived and designed the experiments: HH HS FM NS AF AH CW.
Performed the experiments: HS NS AH. Analyzed the data: HS NS AF
AH. Contributed reagents/materials/analysis tools: HS FM NS AH CW.
Wrote the paper: HH HS NS AH.
References
1. Dziegielewska KM, Brown WM, Casey SJ, Christie DL, Foreman RC, et al.
(1990) The complete cDNA and amino acid sequence of bovine fetuin. Its
homology with alpha 2HS glycoprotein and relation to other members of the
cystatin superfamily. J Biol Chem 265: 4354–4357.
2. Denecke B, Graber S, Schafer C, Heiss A, Woltje M, et al. (2003) Tissue
distribution and activity testing suggest a similar but not identical function of
fetuin-B and fetuin-A. Biochem J 376: 135–145.
3. Auberger P, Falquerho L, Contreres JO, Pages G, Le Cam G, et al. (1989)
Characterization of a natural inhibitor of the insulin receptor tyrosine kinase:
cDNA cloning, purification, and anti-mitogenic activity. Cell 58: 631–640.
4. Rauth G, Poschke O, Fink E, Eulitz M, Tippmer S, et al. (1992) The nucleotide
and partial amino acid sequences of rat fetuin. Identity with the natural tyrosine
kinase inhibitor of the rat insulin receptor. Eur J Biochem 204: 523–529.
5. Srinivas PR, Wagner AS, Reddy LV, Deutsch DD, Leon MA, et al. (1993)
Serum alpha 2-HS-glycoprotein is an inhibitor of the human insulin receptor at
the tyrosine kinase level. Mol Endocrinol 7: 1445–1455.
6. Mathews ST, Srinivas PR, Leon MA, Grunberger G (1997) Bovine fetuin is an
inhibitor of insulin receptor tyrosine kinase. Life Sci 61: 1583–1592.
7. Mathews ST, Chellam N, Srinivas PR, Cintron VJ, Leon MA, et al. (2000)
Alpha2-HSG, a specific inhibitor of insulin receptor autophosphorylation,
interacts with the insulin receptor. Mol Cell Endocrinol 164: 87–98.
8. Mathews ST, Singh GP, Ranalletta M, Cintron VJ, Qiang X, et al. (2002)
Improved insulin sensitivity and resistance to weight gain in mice null for the
Ahsg gene. Diabetes 51: 2450–2458.
9. Siddiq A, Lepretre F, Hercberg S, Froguel P, Gibson F (2005) A synonymous
coding polymorphism in the alpha2-Heremans-schmid glycoprotein gene is
associated with type 2 diabetes in French Caucasians. Diabetes 54: 2477–
2481.
10. Dahlman I, Eriksson P, Kaaman M, Jiao H, Lindgren CM, et al. (2004) alpha2-
Heremans-Schmid glycoprotein gene polymorphisms are associated with
adipocyte insulin action. Diabetologia 47: 1974–1979.
11. Schmidt W, Po ¨ll-Jordan G, Lo ¨ffler G (1990) Adipose conversion of 3T3-L1 cells
in a serum-free culture system depends on epidermal growth factor, insulin-like
growth factor I, corticosterone, and cyclic AMP. J Biol Chem. 15;265:
15489–15495.
12. Kadowaki T, Yamauchi T, Kubota N, Hara K, Ueki K, et al. (2006)
Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the
metabolic syndrome. J Clin Invest 116: 1784–92.
13. Weyer C, Funahashi T, Tanaka S, Hotta K, Matsuzawa Y, et al. (2001)
Hypoadiponectinemia in obesity and type 2 diabetes: close association with
insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab 86:
1930–1935.
14. Stefan N, Vozarova B, Funahashi T, Matsuzawa Y, Weyer C, et al. (2002)
Plasma adiponectin concentration is associated with skeletal muscle insulin
receptor tyrosine phosphorylation, and low plasma concentration precedes a
decrease in whole-body insulin sensitivity in humans. Diabetes 51: 1884–
1888.
15. Tschritter O, Fritsche A, Thamer C, Haap M, Shirkavand F, et al. (2003)
Plasma adiponectin concentrations predict insulin sensitivity of both glucose and
lipid metabolism. Diabetes 52: 239–243.
16. Bacha F, Saad R, Gungor N, Arslanian SA. Adiponectin in youth: relationship
to visceral adiposity, insulin sensitivity, and beta-cell function. Diabetes Care 27:
547–552.
17. Pischon T, Girman CJ, Hotamisligil GS, Rifai N, Hu FB, et al. (2004) Plasma
adiponectin levels and risk of myocardial infarction in men. JAMA 291:
1730–1737.
Fetuin-A and Adiponectin
PLoS ONE | www.plosone.org 8 March 2008 | Volume 3 | Issue 3 | e176518. Iglseder B, Mackevics V, Stadlmayer A, Tasch G, Ladurner G, et al. (2005)
Plasma adiponectin levels and sonographic phenotypes of subclinical carotid
artery atherosclerosis: data from the SAPHIR Study. Stroke 36: 2577–2582.
19. Schulze MB, Shai I, Rimm EB, Li T, Rifai M, et al. (2005) Adiponectin and
future coronary heart disease events among men with type 2 diabetes. Diabetes
54: 534–539.
20. Rothenbacher D, Brenner H, Marz W, Koenig W (2005) Adiponectin, risk of
coronary heart disease and correlations with cardiovascular risk markers. Eur
Heart J 26: 1640–1646.
21. Vionnet N, Hani El-H, Dupont S, Gallina S, Francke S, et al. (200)
Genomewide search for type 2 diabetes-susceptibility genes in French whites:
evidence for a novel susceptibility locus for early-onset diabetes on chromosome
3q27-qter and independent replication of a type 2-diabetes locus on
chromosome 1q21-q24. Am J Hum Genet 67: 1470–1480.
22. Kissebah AH, Sonnenberg GE, Myklebust J, Goldstein M, Broman K, et al.
(2000) Quantitative trait loci on chromosomes 3 and 17 influence phenotypes of
the metabolic syndrome. Proc Natl Acad Sci U S A 97: 14478–14483.
23. Pollin TI, Tanner K, O’connell JR, Ott SH, Damcott CM, et al. (2005) Linkage
of plasma adiponectin levels to 3q27 explained by association with variation in
the APM1 gene. Diabetes 54: 268–274.
24. Stefan N, Hennige AM, Staiger H, Machann J, Schick F, et al. (2006) Alpha2-
Heremans-Schmid glycoprotein/fetuin-A is associated with insulin resistance
and fat accumulation in the liver in humans. Diabetes Care 29: 853–857.
25. Mori K, Emoto M, Yokoyama H, Araki T, Teramura M, et al. (2006)
Association of serum fetuin-A with insulin resistance in type 2 diabetic and
nondiabetic subjects. Diabetes Care 29: 468.
26. Ix JH, Shlipak MG, Brandenburg VM, Ali S, Ketteler M, et al. (2006)
Association between human fetuin-A and the metabolic syndrome: data from the
Heart and Soul Study. Circulation 113: 1760–1767.
27. Trujillo ME, Scherer PE (2006) Adipose tissue-derived factors: impact on health
and disease. Endocr Rev. 2006 27: 762–78.
28. Schling P, Mallow H, Trindl A, Loffler G (1999) Evidence for a local renin
angiotensin system in primary cultured human preadipocytes. Int J Obes Relat
Metab Disord 23: 336–341.
29. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC
(1985) Homeostasis model assessment: insulin resistance and beta-cell function
from fasting plasma glucose and insulin concentrations in man. Diabetologia 28:
412–419.
30. Kershaw EE, Flier JS (2004) Adipose tissue as an endocrine organ. J Clin
Endocrinol Metab 89: 2548–2556.
31. Tsao TS, Murrey HE, Hug C, Lee DH, Lodish HF (2002) Oligomerization
state-dependent activation of NF-kappa B signaling pathway by adipocyte
complement-related protein of 30 kDa (Acrp30). J Biol Chem 277:
29359–29362.
32. Pedersen KO (1944) Fetuin, a new globulin isolated from serum. Nature 154:
575.
33. Jahnen-Dechent W, Schafer C, Heiss A, Grotzinger J (2001) Systemic inhibition
of spontaneous calcification by the serum protein alpha 2-HS glycoprotein/
fetuin. Z Kardiol 90 Suppl 3: 47–56.
34. Schafer C, Heiss A, Schwarz A, Westenfeld R, Ketteler M (2003) The serum
protein alpha 2-Heremans-Schmid glycoprotein/fetuin-A is a systemically acting
inhibitor of ectopic calcification. J Clin Invest 112: 357–366.
35. Ketteler M, Bongartz P, Westenfeld R, Wildberger JE, Mahnken AH, et al.
(2003) Association of low fetuin-A (AHSG) concentrations in serum with
cardiovascular mortality in patients on dialysis: a cross-sectional study. Lancet
361: 827–833.
36. Mori K, Emoto M, Araki T, Yokoyama H, Teramura M, et al. (2007)
Association of serum fetuin-A with carotid arterial stiffness. Clin Endocrinol
(Oxf) 66: 246–50.
37. Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, et al. (2003)
Obesity is associated with macrophage accumulation in adipose tissue. J Clin
Invest 112: 1796–1808.
38. Xu H, Barnes GT, Yang Q, Tan G, Yang D, et al. (2003) Chronic inflammation
in fat plays a crucial role in the development of obesity-related insulin resistance.
J Clin Invest 112: 1821–1830.
39. Lyles JM, Amin W, Bock E, Weill CL (1993) Regulation of NCAM by growth
factors in serum-free myotube cultures. J Neurosci Res 34: 273–286.
40. Ruminy P, Gangneux C, Claeyssens S, Scotte M, Daveau M, et al. (2001) Gene
transcription in hepatocytes during the acute phase of a systemic inflammation:
from transcription factors to target genes. Inflamm Res. 50: 383–390.
41. Hara K, Horikoshi M, Yamauchi T, Yago H, Miyazaki O (2006) Measurement
of the high-molecular weight form of adiponectin in plasma is useful for the
prediction of insulin resistance and metabolic syndrome. Diabetes Care 29:
1357–1362.
42. Fisher FF, Trujillo ME, Hanif W, Barnett AH, McTernan PG, et al. (2005)
Serum high molecular weight complex of adiponectin correlates better with
glucose tolerance than total serum adiponectin in Indo-Asian males. Diabeto-
logia 48: 1084–1087.
43. Lara-Castro C, Luo N, Wallace P, Klein RL, Garvey WT (2006) Adiponectin
multimeric complexes and the metabolic syndrome trait cluster. Diabetes 55:
249–259.
44. Fasshauer M, Klein J, Neumann S, Eszlinger M, Paschke R (2002) Hormonal
regulation of adiponectin gene expression in 3T3-L1 adipocytes. Biochem
Biophys Res Commun 290: 1084–1089.
45. Kappes A, Loffler G (2000) Influences of ionomycin, dibutyryl-cycloAMP and
tumour necrosis factor-alpha on intracellular amount and secretion of apM1 in
differentiating primary human preadipocytes. Horm Metab Res 32: 548–554.
46. Bruun JM, Lihn AS, Verdich C, Pedersen SB, Toubro S, et al. (2003) Regulation
of adiponectin by adipose tissue-derived cytokines: in vivo and in vitro
investigations in humans. Am J Physiol Endocrinol Metab 285: E527–E533.
47. Lihn AS, Richelsen B, Pedersen SB, Haugaard SB, Rathje GS, et al. (2003)
Increased expression of TNF-alpha, IL-6, and IL-8 in HALS: implications for
reduced adiponectin expression and plasma levels. Am J Physiol Endocrinol
Metab 285: E1072–E1080.
48. Fasshauer M, Kralisch S, Klier M, Lossner U, Bluher M, et al. (2003)
Adiponectin gene expression and secretion is inhibited by interleukin-6 in 3T3-
L1 adipocytes. Biochem Biophys Res Commun 301: 1045–1050.
49. Sopasakis VR, Sandqvist M, Gustafson B, Hammarstedt A, Schmelz M, et al.
(2004) High local concentrations and effects on differentiation implicate
interleukin-6 as a paracrine regulator. Obes Res 12: 454–460.
50. Roden M (2006) Mechanisms of Disease: hepatic steatosis in type 2 diabetes–
pathogenesis and clinical relevance. Nat Clin Pract Endocrinol Metab 2:
335–48.
51. Lin X, Braymer HD, Bray GA, York DA (1998) Differential expression of insulin
receptor tyrosine kinase inhibitor (fetuin) gene in a model of diet-induced
obesity. Life Sci 63: 145–153.
52. Chan DC, Barrett HP, Watts GF (2004) Dyslipidemia in visceral obesity:
mechanisms, implications, and therapy. Am J Cardiovasc Drugs 4: 227–246.
53. Lam KS, Xu A (2005) Adiponectin: protection of the endothelium. Curr Diab
Rep 5: 254–259.
54. Santoliquido A, Di Campli C, Miele L, Gabrieli ML, Forgione A, et al. (2005)
Hepatic steatosis and vascular disease. Eur Rev Med Pharmacol Sci 9: 269–271.
Fetuin-A and Adiponectin
PLoS ONE | www.plosone.org 9 March 2008 | Volume 3 | Issue 3 | e1765